Advance of theragnosis biomarkers in lung cancer: from clinical to molecular pathology and biology

被引：6

作者：

Alidousty, Christina ^{[1
]}

Baar, Till ^{[2
]}

Heydt, Carina ^{[1
]}

Wagener-Ryczek, Svenja ^{[1
]}

Kron, Anna ^{[3
,4
,5
]}

Wolf, Juergen ^{[3
,4
,5
]}

Buettner, Reinhard ^{[1
,3
,4
]}

Schultheis, Anne Maria ^{[1
]}

机构：

[1] Univ Hosp Cologne, Inst Pathol, Cologne, Germany

[2] Univ Cologne, Fac Med, Inst Med Stat & Computat Biol, Cologne, Germany

[3] Network Genom Med, Cologne, Germany

[4] Univ Hosp Cologne, Dept Internal Med 1, Lung Canc Grp Cologne, Cologne, Germany

[5] Ctr Integrated Oncol Cologne Bonn, Cologne, Germany

来源：

JOURNAL OF THORACIC DISEASE | 2019年 / 11卷

关键词：

Non-small cell lung cancer (NSCLC); anaplastic lymphoma kinase (ALK); ALK plus -adenocarcinoma; TP53; biomarker; ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB RESISTANCE; PRACTICE GUIDELINES; TARGETED THERAPY; GROWTH-FACTOR; ALK; MUTATIONS; RECEPTOR; IDENTIFICATION; DIAGNOSIS;

D O I：

10.21037/jtd.2018.12.03

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

One distinct molecular subtype of non-small cell lung cancer (NSCLC) is defined by rearrangement of the anaplastic lymphoma kinase (ALK). The increasing knowledge over the last years has enabled the continuous improvement of ALK inhibitors; however, resistance in these patients remains a major concern. In this review, we summarize recent findings in ALK+-adenocarcinoma of the lung, highlighting the role of TP53 mutations in this specific cancer type and suggest new diagnostic strategies for the future, in order to improve patient's outcome.

引用

页码：S3 / S8

页数：6

共 50 条

[21] Deep learning in cancer pathology: a new generation of clinical biomarkers [J].

Echle, Amelie ;

Rindtorff, Niklas Timon ;

Brinker, Titus Josef ;

Luedde, Tom ;

Pearson, Alexander Thomas ;

Kather, Jakob Nikolas .

BRITISH JOURNAL OF CANCER, 2021, 124 (04) :686-696

[22] Impact of the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology clinical practice guidelines for EGFR and ALK testing in lung cancer in Canada [J].

Ionescu, D. N. .

CURRENT ONCOLOGY, 2013, 20 (04) :220-226

[23] Molecular pathology of lung cancer: current status and perspectives [J].

Oberndorfer, Felicitas ;

Muellauer, Leonhard .

CURRENT OPINION IN ONCOLOGY, 2018, 30 (02) :69-76

[24] Practical Value of Molecular Pathology in Stage I–III Lung Cancer: Implications for the Clinical Surgeon [J].

Christopher G. Azzoli .

Annals of Surgical Oncology, 2015, 22 :3459-3465

[25] Pitfalls in Lung Cancer Molecular Pathology: How to Limit them in Routine Practice? [J].

Ilie, M. ;

Hofman, P. .

CURRENT MEDICINAL CHEMISTRY, 2012, 19 (16) :2638-2651

[26] Molecular biomarkers of colorectal cancer: prognostic and predictive tools for clinical practice [J].

Jiang, Wei-qin ;

Fu, Fang-fang ;

Li, Yang-xia ;

Wang, Wei-bin ;

Wang, Hao-hao ;

Jiang, Hai-ping ;

Teng, Li-song .

JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B, 2012, 13 (09) :663-675

[27] Molecular biomarkers of colorectal cancer: prognostic and predictive tools for clinical practice [J].

Wei-qin Jiang ;

Fang-fang Fu ;

Yang-xia Li ;

Wei-bin Wang ;

Hao-hao Wang ;

Hai-ping Jiang ;

Li-song Teng .

Journal of Zhejiang University SCIENCE B, 2012, 13 :663-675

[28] Molecular biomarkers of colorectal cancer:prognostic and predictive tools for clinical practice [J].

Weiqin JIANGFangfang FUYangxia LIWeibin WANGHaohao WANGHaiping JIANGLisong TENGCancer Centerthe First Affiliated HospitalSchool of MedicineZhejiang UniversityHangzhou ChinaInstitute of Infectious Diseasesthe First Affiliated HospitalSchool of MedicineZhejiang UniversityHangzhou China .

Journal of Zhejiang University-Science B(Biomedicine & Biotechnology), 2012, (09) :663-675

[29] A molecular signature of lung cancer: potential biomarkers for adenocarcinoma and squamous cell carcinoma [J].

Shoshan-Barmatz, Varda ;

Bishitz, Yael ;

Paul, Avijit ;

Krelin, Yakov ;

Nakdimon, Itay ;

Peled, Nir ;

Lavon, Avia ;

Rudoy-Zilberman, Elina ;

Refaely, Yael .

ONCOTARGET, 2017, 8 (62) :105492-105509

[30] Molecular Biology that Clinicians Should Know: From a Clinical Viewpoint [J].

Adusumilli, P. .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) :S1639-S1639

← 1 2 3 4 5 →